{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:00:39Z","timestamp":1789124439294,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11060-022-04052-1","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T18:02:41Z","timestamp":1655748161000},"page":"151-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chemotherapy is an efficient treatment in primary CNS MALT lymphoma"],"prefix":"10.1007","volume":"159","author":[{"given":"Cl\u00e9ment","family":"Desjardins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Larrieu-Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Charlotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Nichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Mathon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Le Garff-Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Morales-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dehais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kh\u00ea","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"4052_CR1","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H et al (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94:e1027\u2013e1039. https:\/\/doi.org\/10.1212\/WNL.0000000000008900","journal-title":"Neurology"},{"key":"4052_CR2","volume-title":"World Health Organization classification of tumours of the central nervous system","author":"WHO Classification of Tumours Editorial Board","year":"2021","unstructured":"WHO Classification of Tumours Editorial Board (2021) World Health Organization classification of tumours of the central nervous system, 5th edn. International Agency for Research on Cancer, Lyon","edition":"5"},{"key":"4052_CR3","doi-asserted-by":"publisher","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 89:3909\u20133918 (1997). https:\/\/doi.org\/10.1007\/s001090000086","DOI":"10.1007\/s001090000086"},{"key":"4052_CR4","unstructured":"WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds) WHO classification of tumours, revised 4th edn. Vol 2"},{"key":"4052_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cncr.27773","volume":"119","author":"AJ Olszewski","year":"2013","unstructured":"Olszewski AJ, Castillo JJ (2013) Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database. Cancer 119:629\u2013638. https:\/\/doi.org\/10.1002\/cncr.27773","journal-title":"Cancer"},{"key":"4052_CR6","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3816\/CLM.2009.n.052","volume":"9","author":"W Razaq","year":"2009","unstructured":"Razaq W, Goel A, Amin A, Grossbard ML (2009) Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review. Clin Lymphoma Myeloma 9:E5-9. https:\/\/doi.org\/10.3816\/CLM.2009.n.052","journal-title":"Clin Lymphoma Myeloma"},{"key":"4052_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00277-010-0976-3","volume":"89","author":"S Bayraktar","year":"2010","unstructured":"Bayraktar S, Stefanovic A, Montague N et al (2010) Central nervous system manifestations of marginal zone B-cell lymphoma. Ann Hematol 89:1003\u20131009. https:\/\/doi.org\/10.1007\/s00277-010-0976-3","journal-title":"Ann Hematol"},{"key":"4052_CR8","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1212\/01.wnl.0000218284.23872.eb","volume":"66","author":"FM Iwamoto","year":"2006","unstructured":"Iwamoto FM, DeAngelis LM, Abrey LE (2006) Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology 66:1763\u20131765. https:\/\/doi.org\/10.1212\/01.wnl.0000218284.23872.eb","journal-title":"Neurology"},{"key":"4052_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00000478-199701000-00009","volume":"21","author":"S Kumar","year":"1997","unstructured":"Kumar S, Kumar D, Kaldjian EP et al (1997) Primary low-grade B-cell lymphoma of the dura: a mucosa associated lymphoid tissue-type lymphoma. Am J Surg Pathol 21:81\u201387. https:\/\/doi.org\/10.1097\/00000478-199701000-00009","journal-title":"Am J Surg Pathol"},{"key":"4052_CR10","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.ijrobp.2007.12.007","volume":"71","author":"DR Puri","year":"2008","unstructured":"Puri DR, Tereffe W, Yahalom J (2008) Low-dose and limited-volume radiotherapy alone for primary dural marginal zone lymphoma: treatment approach and review of published data. Int J Radiat Oncol Biol Phys 71:1425\u20131435. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.12.007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4052_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.clml.2017.09.012","volume":"18","author":"A Ayanambakkam","year":"2018","unstructured":"Ayanambakkam A, Ibrahimi S, Bilal K, Cherry MA (2018) Extranodal marginal zone lymphoma of the central nervous system. Clin Lymphoma Myeloma Leuk 18:34-37.e8. https:\/\/doi.org\/10.1016\/j.clml.2017.09.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4052_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.12730","volume":"165","author":"MO Khalil","year":"2014","unstructured":"Khalil MO, Morton LM, Devesa SS et al (2014) Incidence of marginal zone lymphoma in the United States, 2001\u20132009 with a focus on primary anatomic site. Br J Haematol 165:67\u201377. https:\/\/doi.org\/10.1111\/bjh.12730","journal-title":"Br J Haematol"},{"key":"4052_CR13","doi-asserted-by":"publisher","first-page":"5718","DOI":"10.1200\/JCO.2005.17.624","volume":"23","author":"P-H Tu","year":"2005","unstructured":"Tu P-H, Giannini C, Judkins AR et al (2005) Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 23:5718\u20135727. https:\/\/doi.org\/10.1200\/JCO.2005.17.624","journal-title":"J Clin Oncol"},{"key":"4052_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/modpathol.2010.206","volume":"24","author":"G Venkataraman","year":"2011","unstructured":"Venkataraman G, Rizzo KA, Chavez JJ et al (2011) Marginal zone lymphomas involving meningeal dura: possible link to IgG4-related diseases. Mod Pathol 24:355\u2013366. https:\/\/doi.org\/10.1038\/modpathol.2010.206","journal-title":"Mod Pathol"},{"key":"4052_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/cam4.2732","volume":"9","author":"AJ Sunderland","year":"2020","unstructured":"Sunderland AJ, Steiner RE, Al Zahrani M et al (2020) An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Med 9:663\u2013670. https:\/\/doi.org\/10.1002\/cam4.2732","journal-title":"Cancer Med"},{"key":"4052_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/ajcp\/aqaa032","volume":"154","author":"L Nomani","year":"2020","unstructured":"Nomani L, Cotta CV, Hsi ED et al (2020) Extranodal marginal zone lymphoma of the central nervous system includes parenchymal-based cases with characteristic features. Am J Clin Pathol 154:124\u2013132. https:\/\/doi.org\/10.1093\/ajcp\/aqaa032","journal-title":"Am J Clin Pathol"},{"key":"4052_CR17","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJM et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043. https:\/\/doi.org\/10.1200\/JCO.2005.13.524","journal-title":"J Clin Oncol"},{"key":"4052_CR18","doi-asserted-by":"publisher","first-page":"28897","DOI":"10.18632\/oncotarget.25622","volume":"9","author":"D Chihara","year":"2018","unstructured":"Chihara D, Fowler NH, Oki Y et al (2018) Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget 9:28897\u201328902. https:\/\/doi.org\/10.18632\/oncotarget.25622","journal-title":"Oncotarget"},{"key":"4052_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.semcancer.2013.11.005","volume":"24","author":"C Thieblemont","year":"2014","unstructured":"Thieblemont C, Bertoni F, Copie-Bergman C et al (2014) Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Semin Cancer Biol 24:33\u201342. https:\/\/doi.org\/10.1016\/j.semcancer.2013.11.005","journal-title":"Semin Cancer Biol"},{"key":"4052_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-020-03583-9","volume":"149","author":"LD Kaulen","year":"2020","unstructured":"Kaulen LD, Karschnia P, Dietrich J, Baehring JM (2020) Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis. J Neurooncol 149:153\u2013159. https:\/\/doi.org\/10.1007\/s11060-020-03583-9","journal-title":"J Neurooncol"},{"key":"4052_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1684\/bdc.2012.1624","volume":"99","author":"D Psimaras","year":"2012","unstructured":"Psimaras D, Bompaire F, Taillia H et al (2012) Complications neurologiques centrales des chimioth\u00e9rapies cytotoxiques et des th\u00e9rapies cibl\u00e9es. Bull Cancer 99:851\u2013863. https:\/\/doi.org\/10.1684\/bdc.2012.1624","journal-title":"Bull Cancer"},{"key":"4052_CR22","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S0140-6736(09)61299-X","volume":"374","author":"C Soussain","year":"2009","unstructured":"Soussain C, Ricard D, Fike JR et al (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374:1639\u20131651. https:\/\/doi.org\/10.1016\/S0140-6736(09)61299-X","journal-title":"Lancet"},{"key":"4052_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11060-005-1940-2","volume":"75","author":"H Abboud","year":"2005","unstructured":"Abboud H, Carpentier A, Martin-Duverneuil N et al (2005) MALT lymphoma presenting as a meningioma. J Neurooncol 75:221. https:\/\/doi.org\/10.1007\/s11060-005-1940-2","journal-title":"J Neurooncol"},{"key":"4052_CR24","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00277-011-1225-0","volume":"90","author":"T Lim","year":"2011","unstructured":"Lim T, Kim SJ, Kim K et al (2011) Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Ann Hematol 90:1391\u20131398. https:\/\/doi.org\/10.1007\/s00277-011-1225-0","journal-title":"Ann Hematol"},{"key":"4052_CR25","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1200\/JCO.2003.12.054","volume":"21","author":"VS Lima","year":"2003","unstructured":"Lima VS, Leite EB, Fonseca RP, Fernandes AS (2003) Patients presenting with CNS lesions. Case 1. Primary low-grade mucosa-associated B-cell lymphoma of the dura. J Clin Oncol 21:4058\u20134060. https:\/\/doi.org\/10.1200\/JCO.2003.12.054","journal-title":"J Clin Oncol"},{"key":"4052_CR26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/10428194.2016.1218006","volume":"58","author":"MI de la Fuente","year":"2017","unstructured":"de la Fuente MI, Haggiagi A, Moul A et al (2017) Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami Experiences. Leuk Lymphoma 58:882\u2013888. https:\/\/doi.org\/10.1080\/10428194.2016.1218006","journal-title":"Leuk Lymphoma"},{"key":"4052_CR27","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.4081\/hr.2010.e10","volume":"2","author":"K Matmati","year":"2010","unstructured":"Matmati K, Matmati N, Hannun YA et al (2010) Dural MALT lymphoma with disseminated disease. Hematol Rep 2:e10. https:\/\/doi.org\/10.4081\/hr.2010.e10","journal-title":"Hematol Rep"},{"key":"4052_CR28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1080\/10428190500178472","volume":"46","author":"S Knop","year":"2005","unstructured":"Knop S, Herrlinger U, Ernemann U et al (2005) Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia. Leuk Lymphoma 46:1593\u20131598. https:\/\/doi.org\/10.1080\/10428190500178472","journal-title":"Leuk Lymphoma"},{"key":"4052_CR29","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3389\/fonc.2020.01523","volume":"10","author":"L Zhao","year":"2020","unstructured":"Zhao L, Zhao W, Hou Y et al (2020) An overview of Managements in Meningiomas. Front Oncol 10:1523","journal-title":"Front Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04052-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:28:12Z","timestamp":1659104892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04052-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4052"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04052-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"29 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Within the framework of the LOC national expert network database, all patients signed written consent for the use of their medical data for clinical research purposes while respecting their anonymity. This database has been authorized by the CNIL (Commission Nationale de l'Informatique et des Libert\u00e9s) and the CPPRB (Comit\u00e9 de Protection des Personnes en Recherche Biom\u00e9dicale) and was therefore in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This is an observational study. It was approved by an Institutional Ethical Committee and by the French \u201cCommission Nationale de l\u2019Informatique et des Libert\u00e9s\u201d (CNIL).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}